Abstracts tagged "ANA"

Abstract Number: 18 • 2013 ACR/ARHP Annual Meeting
Clinical Correlates Of Positive Anti-Cardiolipin and β-2 Glycoprotein 1 Antibodies In a Cohort Of 110 Patients At Mayo Clinic
Uma Thanarajasingam¹, Cynthia S. Crowson², Melissa R. Snyder³, Rajeev Pruthi⁴, Harvinder S. Luthra⁵ and Kevin G. Moder⁶, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³2Division of Clinical Biochemistry and Immunology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, ⁴Divison of Hematology, Mayo Clinic, Rochester, MN, ⁵Medicine/Division of Rheum, Mayo Clinic, Rochester, MN, ⁶Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Testing for antiphospholipid antibodies is typically indicated for diagnosis and prognosis of antiphospholipid syndromes, however, selected patients undergo testing for other reasons. The clinical…
Abstract Number: 2598 • 2013 ACR/ARHP Annual Meeting
Timing and Outcome Of Transition From Primary To Secondary Raynaud’s Phenomenon: A Capillaroscopic Based Study
Alberto Sulli¹, Giorgia Ferrari², Elena Bernero², Carmen Pizzorni², Vanessa Smith³, Barbara Ruaro² and Maurizio Cutolo⁴, ¹Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ³Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁴Internal medicine, Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy
Background/Purpose: Raynaud's phenomenon (RP) is classified as primary (PRP) or secondary (SRP) depending on its association with an underlying disease (1,2). PRP can evolve to…
Abstract Number: 2575 • 2013 ACR/ARHP Annual Meeting
Utility Of Autoantibody Testing For Predicting Risk Of Pulmonary Arterial Hypertension: A Retrospective Analysis In Routine Autoantibody Laboratory
Masataka Kuwana¹, Yuichiro Shirai¹, Hidekata Yasuoka¹, Tsutomu Takeuchi¹ and Kenichi Masui², ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Department of Anesthesiology, National Defense Medical College, Tokorozawa, Japan
Background/Purpose: Pulmonary arterial hypertension (PAH) is an intractable complication of connective tissue disease (CTD). Current guidelines recommend early detection and intervention for improvement of outcomes.…
Abstract Number: 2586 • 2013 ACR/ARHP Annual Meeting
Antinuclear Antibody Negative Systemic Sclerosis Patients Have Less Vasculopathic Disease Manifestations
Gloria Salazar¹, Shervin Assassi¹, Fredrick M. Wigley², Daniel Furst^3,4,5, Laura K. Hummers², Dinesh Khanna⁶, John Varga⁷, Elena Schiopu⁸, Virginia D. Steen⁹, Murray Baron¹⁰, Marie Hudson¹¹, Janet E. Pope^12,13, Monique E. Hinchcliff¹⁴, Marvin J. Fritzler¹⁵, David B. Robinson¹⁶, Robert W. Simms¹⁷, Richard M. Silver¹⁸, Tracy M. Frech¹⁹, Barri J. Fessler²⁰, Jerry A. Molitor²¹, Sara Zamanian²², Niall Jones²³, John D. Reveille¹, Frank C. Arnett¹ and Maureen D. Mayes²⁴, ¹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA, ⁴Div of Rheumatology, UCLA Medical School, Los Angeles, CA, ⁵Rheumatology, UCLA, Los Angeles, CA, ⁶University of Michigan Health System, Ann Arbor, MI, ⁷Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁸Rheumatology/Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, ⁹Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ¹⁰McGill University, Montreal, QC, Canada, ¹¹Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ¹²Univ of Western Ontario, London, ON, Canada, ¹³St Joseph Health Care, London, ON, Canada, ¹⁴Division of Rheumatology, Northwestern University Medical School, Chicago, IL, ¹⁵Medicine, University of Calgary, Calgary, AB, Canada, ¹⁶Arthritis Centre, University of Manitoba, Winnipeg, MB, Canada, ¹⁷Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁸Div Rheumatology & Immunology, Medical University of South Carolina,Charleston,USA, Charleston, SC, ¹⁹Internal Medicine-Division of Rheumatology, University of Utah School of Medicine, SLC, UT, ²⁰Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²¹Rheumatic/Autoimmune Diseases, Univ of MN MMC108, Minneapolis, MN, ²²Internal Medicine/Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²³Rheumatology Clinic at 124th Street Medical Clinic, Edmonton, AB, Canada, ²⁴University of Texas Health Science Center at Houston, Houston, TX
Antinuclear Antibody Negative Systemic Sclerosis Patients Have Less Vasculopathic Disease ManifestationsBackground/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease characterized by fibrosis of skin and internal…
Abstract Number: 2539 • 2013 ACR/ARHP Annual Meeting
The Reliability Of a Novel Automated System For ANA Immunofluorescence Analysis In Daily Clinical Practice
Mohammed Alsuwaidi¹, Margit Dollinger¹, Martin Fleck^1,2 and Boris P. Ehrenstein¹, ¹Rheumatology & Clinical Immunology, Asklepios Clinic Bad Abbach, Bad Abbach, Germany, ²Internal Medicine I, University Medical Center of Regensburg, Regensburg, Germany
Background/Purpose: Recently, automated interpretation (AI) systems for anti-nuclear antibody (ANA) analysis have been introduced based on assessment of indirect immunofluorescence (IIF) patterns. However, the reliability…
Abstract Number: 1927 • 2013 ACR/ARHP Annual Meeting
Assessing Adherence To Choosing Wisely® Recommendations Regarding Antinuclear Antibody and Antinuclear Antibody Subserology Testing In An Urban Community Health System
Adam Carlson¹, Jinoos Yazdany², Kara Lynch³ and Laura Trupin², ¹Medicine, UC San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA, ³Laboratory Medicine, San Francisco General Hospital, San Francisco, CA
Background/Purpose: As part of the American Board of Internal Medicine's Choosing Wisely Campaign®, the ACR published recommendations in 2013 advising clinicians against ordering anti-nuclear…
Abstract Number: 846 • 2013 ACR/ARHP Annual Meeting
Applying Choosing Wisely: Identifying Inefficiencies Of Antinuclear Antibody Subserology Testing In a Safety Net Health System
Lisa A. Davis¹, Barbara L. Goldstein², Vivian Tran¹, Angela Keniston³, Jinoos Yazdany⁴, Joel M. Hirsh¹, Amy Storfa⁵ and Joann Zell², ¹Medicine, Division of Rheumatology, Denver Health and Hospital Authority, Denver, CO, ²Medicine, National Jewish Health, Denver, CO, ³Department of Medicine, Denver Health and Hospital Authority, Denver, CO, ⁴Medicine, University of California, San Francisco, San Francisco, CA, ⁵Medicine, Denver Health and Hospital Authority, Denver, CO
Applying Choosing Wisely®: Identifying Inefficiencies of ANA (antinuclear antibody) Subserology Testing in a Safety Net Health System Background/Purpose: In 2013, the American College of…
Abstract Number: 847 • 2013 ACR/ARHP Annual Meeting
Do Rheumatologists (and Other Specialists) Practice What We Preach? A Study Of Serology Ordering Patterns With Attention To Subserologies When The Antinuclear Antibody By Enzyme Linked Immunosorbent Assay Is Negative; And The Clinical Significance Of These Positive Subserology Results
David Bulbin¹, Alicia Meadows¹, Alfred E. Denio², H. Lester Kirchner³, Sandi Kelsey⁴ and Harold Harrison⁴, ¹Dept of General Internal Medicine, Geisinger Medical Center, Danville, PA, ²Dept of Rheumatology, Geisinger Health System, Danville, PA, ³Geisinger Center for Health Research, Geisinger Health System, Danville, PA, ⁴Dept of Pathology, Geisinger Medical Center, Danville, PA
Background/Purpose: The American College of Rheumatology (ACR) was asked by the American Board of Internal Medicine to contribute to the “Choosing Wisely” campaign. The first…
Abstract Number: 106 • 2013 ACR/ARHP Annual Meeting
Antinuclear Antibodies Positive But No Autoimmune Disease
M Herold¹ and Werner Klotz², ¹Internal Medicine VI, Medical University of Innsbruck, Innsbruck, Austria, ²Internal Medicine VI, Innsbruck Medical University, Innsbruck, Austria
Background/Purpose: Antinuclear antibodies (ANAs) are tested in sera of patients suspicious of an autoimmune disorder. ANAs are part in many classification criteria of autoimmune (AI)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].